eli lilly news glp-1 FDA approves Lilly's weight loss pill – Boston 25 FDA approves Eli Lilly's GLP-1

NAION = non-arteritic anterior ischemic optic neuropathy is a rare cause of blindness and has been reported at higher rates in those taking GLP1s

L-Lysine Butyrate (BIOMEnd )

Payors gain a clearer pathway to lower dispensing costs and broader access

Track doses, manage side effects, reduce food noise, and build habits that actually stick.

Discover the difference between Miralax and Metamucil, why fiber makes it worse, and how to get relief.

Beyond GLP-1: The Next Frontier in Cardiometabolic Medicine The STEER study reinforces what SELECT hinted: Semaglutide (Wegovy) may deliver cardiovascular protection beyond weight loss alonewith signals of reduced inflammation, improved endothelial function, and greater plaque stability